Darragh McArt
Darragh McArt
Потвърден имейл адрес: qub.ac.uk
QuPath: Open source software for digital pathology image analysis
P Bankhead, MB Loughrey, JA Fernández, Y Dombrowski, DG McArt, ...
Scientific reports 7 (1), 1-7, 2017
Digital pathology and image analysis in tissue biomarker research
PW Hamilton, P Bankhead, Y Wang, R Hutchinson, D Kieran, DG McArt, ...
Methods 70 (1), 59-73, 2014
Validation of next generation sequencing technologies in comparison to current diagnostic gold standards for BRAF, EGFR and KRAS mutational analysis
CM McCourt, DG McArt, K Mills, MA Catherwood, P Maxwell, DJ Waugh, ...
PLoS One 8 (7), e69604, 2013
Challenging the cancer molecular stratification dogma: intratumoral heterogeneity undermines consensus molecular subtypes and potential diagnostic value in colorectal cancer
PD Dunne, DG McArt, CA Bradley, PG O'Reilly, HL Barrett, R Cummins, ...
Clinical Cancer Research 22 (16), 4095-4104, 2016
AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer
PD Dunne, DG McArt, JK Blayney, M Kalimutho, S Greer, T Wang, ...
Clinical Cancer Research 20 (1), 164-175, 2014
EphA2 expression is a key driver of migration and invasion and a poor prognostic marker in colorectal cancer
PD Dunne, S Dasgupta, JK Blayney, DG McArt, KL Redmond, JA Weir, ...
Clinical Cancer Research 22 (1), 230-242, 2016
Development and validation of a 28-gene hypoxia-related prognostic signature for localized prostate cancer
L Yang, D Roberts, M Takhar, N Erho, BAS Bibby, N Thiruthaneeswaran, ...
EBioMedicine 31, 182-189, 2018
Prognostic and therapeutic relevance of FLIP and procaspase-8 overexpression in non-small cell lung cancer
JS Riley, R Hutchinson, DG McArt, N Crawford, C Holohan, I Paul, ...
Cell death & disease 4 (12), e951-e951, 2013
The prognostic significance of the aberrant extremes of p53 immunophenotypes in breast cancer
DP Boyle, DG McArt, G Irwin, CS Wilhelm‐Benartzi, TF Lioe, E Sebastian, ...
Histopathology 65 (3), 340-352, 2014
Integrated tumor identification and automated scoring minimizes pathologist involvement and provides new insights to key biomarkers in breast cancer
P Bankhead, JA Fernández, DG McArt, DP Boyle, G Li, MB Loughrey, ...
Laboratory investigation 98 (1), 15-26, 2018
Cancer-cell intrinsic gene expression signatures overcome intratumoural heterogeneity bias in colorectal cancer patient classification
PD Dunne, M Alderdice, PG O'Reilly, AC Roddy, AMB McCorry, ...
Nature communications 8 (1), 1-12, 2017
Modelling the comet assay
DG McArt, G McKerr, CV Howard, K Saetzler, GR Wasson
Biochemical Society Transactions 37 (4), 914-917, 2009
Identification of candidate small-molecule therapeutics to cancer by gene-signature perturbation in connectivity mapping
DG McArt, SD Zhang
PloS one 6 (1), e16382, 2011
Transcriptional subtyping and CD8 immunohistochemistry identifies patients with stage II and III colorectal cancer with poor prognosis who benefit from adjuvant chemotherapy
WL Allen, PD Dunne, S McDade, E Scanlon, M Loughrey, HG Coleman, ...
JCO precision oncology 2, 1-15, 2018
Prospective patient stratification into robust cancer‐cell intrinsic subtypes from colorectal cancer biopsies
M Alderdice, SD Richman, S Gollins, JP Stewart, C Hurt, R Adams, ...
The Journal of pathology 245 (1), 19-28, 2018
Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer
RA Hutchinson, RA Adams, DG McArt, M Salto-Tellez, B Jasani, ...
Journal of translational medicine 13 (1), 1-11, 2015
Automated tumor analysis for molecular profiling in lung cancer
PW Hamilton, Y Wang, C Boyd, JA James, MB Loughrey, JP Hougton, ...
Oncotarget 6 (29), 27938, 2015
Quantification of HER2 heterogeneity in breast cancer–implications for identification of sub-dominant clones for personalised treatment
NE Buckley, C Forde, DG McArt, DP Boyle, PB Mullan, JA James, ...
Scientific reports 6 (1), 1-8, 2016
Comprehensive molecular pathology analysis of small bowel adenocarcinoma reveals novel targets with potential for clinical utility
MA Alvi, DG McArt, P Kelly, MA Fuchs, M Alderdice, CM McCabe, ...
Oncotarget 6 (25), 20863, 2015
TBX2 represses CST6 resulting in uncontrolled legumain activity to sustain breast cancer proliferation: a novel cancer-selective target pathway with therapeutic opportunities.
ZC D'Costa, C Higgins, CW Ong, GW Irwin, D Boyle, DG McArt, ...
Oncotarget 5 (6), 1609, 2014
Системата не може да изпълни операцията сега. Опитайте отново по-късно.
Статии 1–20